Diabetes Screening among Antipsychotic-Treated Adults with Severe Mental Illness in an Integrated Delivery System: A Retrospective Cohort Study
- 31 October 2017
- journal article
- research article
- Published by Springer Nature in Journal of General Internal Medicine
- Vol. 33 (1) , 79-86
Abstract
Severe mental illness (SMI) is associated with increased risk for type 2 diabetes, partly due to adverse metabolic effects of antipsychotic medications. In public health care settings, annual screening rates are 30%. We measured adherence to national diabetes screening guidelines for patients taking antipsychotic medications.Keywords
This publication has 29 references indexed in Scilit:
- The Table 2 Fallacy: Presenting and Interpreting Confounder and Modifier CoefficientsAmerican Journal of Epidemiology, 2013
- Cigarette Smoking and Mortality Risk in People With SchizophreniaSchizophrenia Bulletin, 2009
- Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and AdolescentsJAMA, 2009
- Care and management of cardiovascular risk factors among individuals with schizophrenia and type 2 diabetes who smokeGeneral Hospital Psychiatry, 2009
- Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: Systematic review and metaanalysisBMC Psychiatry, 2008
- Educational Disparities in Rates of Smoking Among Diabetic Adults: The Translating Research Into Action for Diabetes StudyAmerican Journal of Public Health, 2008
- Drug Use Patterns in Severely Mentally Ill Medicare Beneficiaries: Impact of Discontinuities in Drug CoverageHealth Services Research, 2007
- Second-Generation (Atypical) Antipsychotics and Metabolic EffectsCNS Drugs, 2005
- Consensus Development Conference on Antipsychotic Drugs and Obesity and DiabetesDiabetes Care, 2004
- The assessment of refill compliance using pharmacy records: Methods, validity, and applicationsJournal of Clinical Epidemiology, 1997